Orbital metastasis from thyroid cancer: a case report and review of the literature.

Thyroid cancer case report chemo and radiotherapy non-Hodgkin lymphoma orbital metastases

Journal

Annals of palliative medicine
ISSN: 2224-5839
Titre abrégé: Ann Palliat Med
Pays: China
ID NLM: 101585484

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 12 01 2022
accepted: 18 04 2022
pubmed: 14 6 2022
medline: 15 11 2022
entrez: 13 6 2022
Statut: ppublish

Résumé

Differentiated thyroid cancer (DTC) is generally associated with an excellent prognosis. However up to 20% of DTC patients have disease events during subsequent follow-up; rarely patients present an aggressive disease with distant metastases (DM), mainly in the lung and bone. Metastases at unusual sites may also occur, generally in patients with disseminated disease. Orbital localization is rare and only few cases have been described so far. A 36 years-old man, treated with chemo and radiotherapy during childhood for non-Hodgkin lymphoma, was referred for suspicious lymph node (LN) and multiple lung metastases. Total thyroidectomy and latero-cervical (LC) lymphadenectomy were performed: papillary thyroid cancer (PTC), 25 mm, 11/17 LN metastases; pT2N1bM1. Post-treatment total body scan with I-131 showed LN and lung uptake. Eighteen months from diagnosis he presented progressive diplopia, proptosis and right exophthalmos due to an 18 mm orbital metastasis. Hence, due to I-131 refractoriness for structural disease progression despite I-131 therapy, he started therapy with Lenvatinib for 6 months, with initial partial response followed by disease progression, and then with Cabozantinib, which he stopped after 6 months for adverse events and disease progression after therapy reduction. Currently, the patient is receiving Lenvatinib, rechallenge therapy, with disease stabilization and biochemical response. Molecular analysis, performed on both primary and relapsed tumor didn't show any significant pathogenic alteration. This case of DTC with an unusual metastasis in the orbit, may suggest that patient's exposure to chemo- and radiotherapy during pediatric age might have played a role in the subsequent development of this unusually aggressive tumor, reinforcing the recommendation of long-term and intensive follow-up of these patients.

Sections du résumé

BACKGROUND BACKGROUND
Differentiated thyroid cancer (DTC) is generally associated with an excellent prognosis. However up to 20% of DTC patients have disease events during subsequent follow-up; rarely patients present an aggressive disease with distant metastases (DM), mainly in the lung and bone. Metastases at unusual sites may also occur, generally in patients with disseminated disease. Orbital localization is rare and only few cases have been described so far.
CASE DESCRIPTION METHODS
A 36 years-old man, treated with chemo and radiotherapy during childhood for non-Hodgkin lymphoma, was referred for suspicious lymph node (LN) and multiple lung metastases. Total thyroidectomy and latero-cervical (LC) lymphadenectomy were performed: papillary thyroid cancer (PTC), 25 mm, 11/17 LN metastases; pT2N1bM1. Post-treatment total body scan with I-131 showed LN and lung uptake. Eighteen months from diagnosis he presented progressive diplopia, proptosis and right exophthalmos due to an 18 mm orbital metastasis. Hence, due to I-131 refractoriness for structural disease progression despite I-131 therapy, he started therapy with Lenvatinib for 6 months, with initial partial response followed by disease progression, and then with Cabozantinib, which he stopped after 6 months for adverse events and disease progression after therapy reduction. Currently, the patient is receiving Lenvatinib, rechallenge therapy, with disease stabilization and biochemical response. Molecular analysis, performed on both primary and relapsed tumor didn't show any significant pathogenic alteration.
CONCLUSIONS CONCLUSIONS
This case of DTC with an unusual metastasis in the orbit, may suggest that patient's exposure to chemo- and radiotherapy during pediatric age might have played a role in the subsequent development of this unusually aggressive tumor, reinforcing the recommendation of long-term and intensive follow-up of these patients.

Identifiants

pubmed: 35695049
doi: 10.21037/apm-22-61
pii: apm-22-61
doi:

Substances chimiques

lenvatinib EE083865G2
Iodine-131 0
Iodine Radioisotopes 0

Types de publication

Review Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

3346-3355

Auteurs

Giulia Sapuppo (G)

Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy; Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, Policlinico "G. Rodolico-San Marco" Medical Center, Catania, Italy.

Federica Martorana (F)

Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, Policlinico "G. Rodolico-San Marco" Medical Center, Catania, Italy.

Elena Tirrò (E)

Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, Policlinico "G. Rodolico-San Marco" Medical Center, Catania, Italy; Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy.

Rosario Le Moli (R)

Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.

Romilda Masucci (R)

Clinical and Diagnostic Center, G.B. Morgagni, Catania, Italy.

Lelio Baldeschi (L)

Department of Ophthalmology, Hospital Saint Luc, Catholic University of Louvain, Brussels, Belgium.

Corrado Spatola (C)

Department of Oncological Radiotherapy, "G. Rodolico-San Marco" Medical Center, Catania, Italy.

Antonino Belfiore (A)

Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Medical Center, Catania, Italy.

Paolo Vigneri (P)

Center of Experimental Oncology and Hematology, Department of Clinical and Experimental Medicine, Policlinico "G. Rodolico-San Marco" Medical Center, Catania, Italy.

Gabriella Pellegriti (G)

Endocrinology, Garibaldi-Nesima Medical Center, Catania, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH